−0.0074USD
−3.10 MUSD
557.71 KUSD
385.53 M
About Provectus Biopharmaceuticals, Inc.
Sector
Industry
CEO
Dominic Rodrigues
Website
Headquarters
Knoxville
Employees (FY)
4
Founded
2002
ISIN
US74373P1084
FIGI
BBG000PGR5K3
Provectus Biopharmaceuticals, Inc. is a development stage biopharmaceutical company, which engages in the development of ethical pharmaceuticals for oncology and dermatology indications. Its prescription drugs treat several life-threatening cancers including metastatic melanoma, liver cancer, and breast cancer. The company was founded by Eric A. Wachter in 2002 and is headquartered in Knoxville, TN.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of PVCT is 0.18 USD — it has increased by 4.48% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Provectus Biopharmaceuticals, Inc. stocks are traded under the ticker PVCT.
Provectus Biopharmaceuticals, Inc. is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
Yes, you can track Provectus Biopharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, PVCT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Provectus Biopharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 16, 2024, the company has 4.00 employees. See our rating of the largest employees — is Provectus Biopharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Provectus Biopharmaceuticals, Inc. EBITDA is −2.87 M USD, and current EBITDA margin is −522.95%. See more stats in Provectus Biopharmaceuticals, Inc. financial statements.